Wedbush reissued their outperform rating on shares of Miragen Therapeutics (NASDAQ:MGEN) in a research note issued to investors on Tuesday morning. Wedbush also issued estimates for Miragen Therapeutics’ FY2022 earnings at ($0.96) EPS.

A number of other analysts have also recently commented on MGEN. Deutsche Bank assumed coverage on shares of Miragen Therapeutics in a report on Thursday. They set a buy rating and a $15.00 target price on the stock. Zacks Investment Research raised Miragen Therapeutics from a hold rating to a buy rating and set a $10.00 price target for the company in a research report on Tuesday, January 9th. Oppenheimer started coverage on Miragen Therapeutics in a research report on Friday, January 12th. They issued an outperform rating and a $13.00 price target for the company. Evercore ISI started coverage on Miragen Therapeutics in a research report on Friday, March 9th. They issued an outperform rating and a $19.00 price target for the company. Finally, B. Riley started coverage on Miragen Therapeutics in a research report on Friday, January 5th. They issued a buy rating and a $15.50 price target for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus price target of $16.59.

How to Become a New Pot Stock Millionaire

Shares of Miragen Therapeutics (MGEN) opened at $7.61 on Tuesday. Miragen Therapeutics has a fifty-two week low of $5.01 and a fifty-two week high of $15.91. The company has a market cap of $229.01, a price-to-earnings ratio of -5.07 and a beta of 1.64. The company has a current ratio of 13.33, a quick ratio of 13.33 and a debt-to-equity ratio of 0.26.

Miragen Therapeutics (NASDAQ:MGEN) last announced its earnings results on Wednesday, March 14th. The medical research company reported ($0.29) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.33) by $0.04. Miragen Therapeutics had a negative net margin of 662.30% and a negative return on equity of 63.57%. The firm had revenue of $1.19 million for the quarter, compared to analysts’ expectations of $1.22 million. sell-side analysts forecast that Miragen Therapeutics will post -1.25 earnings per share for the current year.

In related news, Director Bruce Booth purchased 545,454 shares of the stock in a transaction dated Tuesday, February 13th. The stock was purchased at an average price of $5.50 per share, with a total value of $2,999,997.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Adam Scott Levy purchased 9,090 shares of the stock in a transaction dated Tuesday, February 13th. The stock was bought at an average cost of $5.50 per share, with a total value of $49,995.00. Following the transaction, the insider now owns 10,540 shares in the company, valued at $57,970. The disclosure for this purchase can be found here. 44.40% of the stock is owned by insiders.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Deutsche Bank AG raised its position in shares of Miragen Therapeutics by 437.4% in the 4th quarter. Deutsche Bank AG now owns 60,917 shares of the medical research company’s stock worth $634,000 after purchasing an additional 49,581 shares during the last quarter. Renaissance Technologies LLC purchased a new position in Miragen Therapeutics in the 4th quarter worth about $855,000. Virtu Financial LLC raised its position in Miragen Therapeutics by 372.8% in the 4th quarter. Virtu Financial LLC now owns 51,896 shares of the medical research company’s stock worth $541,000 after buying an additional 40,920 shares during the last quarter. BlackRock Inc. raised its position in Miragen Therapeutics by 4.7% in the 4th quarter. BlackRock Inc. now owns 574,917 shares of the medical research company’s stock worth $5,997,000 after buying an additional 25,704 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its position in Miragen Therapeutics by 67.1% in the 4th quarter. Bank of New York Mellon Corp now owns 45,775 shares of the medical research company’s stock worth $478,000 after buying an additional 18,374 shares during the last quarter. 19.83% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This news story was reported by Daily Political and is owned by of Daily Political. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of United States and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.dailypolitical.com/2018/03/23/wedbush-reaffirms-outperform-rating-for-miragen-therapeutics-mgen.html.

About Miragen Therapeutics

Signal Genetics, Inc is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test.

Analyst Recommendations for Miragen Therapeutics (NASDAQ:MGEN)

Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.